Open House rebate agreements 2026-22 - Ustekinumab

Summary

The tender concerns rebate agreements for medicines containing the active substance ustekinumab. It is an open-house procedure in which agreements are concluded with all suitable pharmaceutical companies on uniform terms; there are no individual negotiations and no exclusivity is granted. The contract term is up to 12 months starting on 01/08/2026 and ends no later than 31/07/2027. The contract may be extended by 12 months. The detailed participation and contract conditions must be checked in the tender documents.